Last updated 15 days ago
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
1063 patients around the world
Available in Argentina, Mexico
Eli Lilly and Company
5Research sites
1063Patients around the world
This study is for people with
Ulcerative colitis
Moderate/severe ulcerative colitis
Requirements for the patient
To 80 Years
All Gender
Medical requirements
- Participants from Study AMAC (NCT02589665) or AMBG (NCT03524092) who have had at least one study drug administration and have not had early termination of study drug.Female participants must agree to contraception requirements.
- Participants must not have developed a new condition, including cancer in the originator study.Participants must not have any important infections including, but not limited to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during either originator studyParticipants may not have received surgery for UC in the originator study or are likely to require surgery for treatment of UC during the study.Participants must not have developed adenomatous polyps during the originator study that have not been removed prior to the start of this study.
Sites
CER Instituto Médico - Quilmes, Buenos Aires
Recruiting
Instituto de Investigaciones Clínicas Quilmes
Recruiting
Glenny Corp S.A.
Recruiting
Instituto Médico de la Fundación Estudios Clínicos - Rosario
Recruiting
Mautalen - Salud e Investigación - CABA
Recruiting
StudyLUCENT 3
SponsorEli Lilly and Company
Study typeInterventional
Conditions
Moderate/severe ulcerative colitis
Requirements
To 80 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT03519945
